Saturday, 5 September 2026European Markets

FINATIS Stock Slides By 19% In The Last 5 Sessions

Loading stream...

(vianews) - shares of finatis (cac 40: fnts.pa) dropped by a staggering 19.6% in 5 sessions from €5 to €4.02 at 14:54 est on wednesday, after five consecutive sessions in a row of losses. cac 40 is falling 0.59% to €7,326.38, after two consecutive sessions in a row of losses.

about finatis

finatis société anonyme operates in the food distribution business in france and latin america. it operates monoprix, franprix, casino supermarkets, petit casinos, casino shops, spars, vivals, géant hypermarkets, etc. the company also distributes sports equipment under the go sport brand; and invests in real estate properties, as well as manages a portfolio of private equity investments. the company was incorporated in 1971 and is headquartered in paris, france. finatis société anonyme is a subsidiary of euris sas.

earnings per share

as for profitability, finatis has a trailing twelve months eps of €-24.26.

volume

today's last reported volume for finatis is 48 which is 63.35% below its average volume of 131.

more news about finatis (fnts.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com